Third Quarter 2019 Results

Bayer AG News Conference Call

Bayer: Encouraging business performance across all divisions – agreements signed to divest Currenta and Animal Health

  • Group sales increase by 5.4 percent (Fx & portfolio adj.) to 9.830 billion euros/li>
  • EBITDA before special items advances by 7.5 percent to 2.291 billion euros
  • Crop Science reports higher sales and substantial earnings growth
  • Pharmaceuticals increases sales – earnings decline due to one-time income in prior year
  • Consumer Health posts growth in sales (Fx & portfolio adj.) and earnings
  • Net income declines by 63.9 percent to 1.036 billion euros – substantial divestment gain included in prior year
  • Core earnings per share up by 6.4 percent to 1.16 euros
  • Group outlook confirmed and aligned to continuing operations



Werner Baumann, CEO of Bayer AG

Werner Baumann
CEO of Bayer AG

Wolfgang Nickl, CFO of Bayer AG

Wolfgang Nickl
CFO of Bayer AG

Follow us:


You will find the key statements on ? Twitter